The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

被引:6
|
作者
Bragina, Olga D. [1 ,2 ]
Deyev, Sergei M. [2 ,3 ]
Chernov, Vladimir, I [1 ,2 ]
Tolmachev, Vladimir M. [2 ,4 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Tomsk 634009, Russia
[2] Natl Res Tomsk Polytech Univ, Tomsk 634050, Russia
[3] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[4] Uppsala Univ, Uppsala, Sweden
来源
ACTA NATURAE | 2022年 / 14卷 / 02期
关键词
breast cancer; HER2/neu; radionuclide diagnostics; monoclonal antibody; alternative scaffold proteins; HER2; EXPRESSION; THERAPEUTIC TARGETS; RECEPTOR; THERANOSTICS; TRASTUZUMAB; DISCORDANCE; CONCORDANCE; METASTASES; BIOMARKERS; GUIDELINES;
D O I
10.32607/actanaturae.11611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 50 条
  • [41] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [42] Optimizing Treatment of HER2-Positive Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 649 - 651
  • [44] Adjuvant Therapy for HER2-Positive Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [45] Hormonotherapy in patients with HER2-positive breast cancer
    Debska, Sylwia
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 (06): : 301 - 310
  • [46] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [47] Brain metastases in HER2-positive breast cancer
    Lin, Nancy U.
    LANCET ONCOLOGY, 2013, 14 (03): : 185 - 186
  • [48] Cardiotoxicity in HER2-positive breast cancer patients
    Gonciar, Diana
    Mocan, Lucian
    Zlibut, Alexandru
    Mocan, Teodora
    Agoston-Coldea, Lucia
    HEART FAILURE REVIEWS, 2021, 26 (04) : 919 - 935
  • [49] Is there a role for immunotherapy in HER2-positive breast cancer?
    Holgado, Esther
    Perez-Garcia, Jose
    Gion, Maria
    Cortes, Javier
    NPJ BREAST CANCER, 2018, 4
  • [50] Adjuvant treatment for HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (02): : E59 - E59